Article: Wyeth Stops Heart Attack Study; Neose Loses Manufacturing Deal.

Article: Neose Technologies Announces Collaboration and License ...
Business Wire;  November 8, 1999 ;     700+ words ... ... collaboration with Neose," said Brian Sparg, Wyeth Nutritionals Group ... infant nutrition." "Neose looks forward to a close collaboration with Wyeth," said Stephen Roth ... Executive Officer of Neose. "Wyeth is clearly committed ...

Article: Neose Signs R&D and Licensing Agreement with ...
PR Newswire;  December 19, 2001 ;     700+ words ... ... During commercial production of Wyeth's current rPSGL-Ig, Neose will receive ongoing payments ... ongoing product payments, Neose and Wyeth will also enter into a supply ... Neose's Chairman and CEO. "Wyeth and Neose have worked together extensively ...

Article: Neose Signs R&D and Licensing Agreement With ...
Heart Disease Weekly;  January 20, 2002 ;     700+ words ... ... During commercial production of Wyeth's current rPSGL-Ig, Neose will receive ongoing payments ... ongoing product payments, Neose and Wyeth will also enter into a supply ... GlycoAdvance process reagents. "Wyeth and Neose have worked together extensively ...

Article: Neose, Wyeth link-up for CHO ingredient for ...
Nutraceuticals International;  December 1, 1999 ;     337 words ...Neose has entered into a collaboration with American Home Products' subsidiary Wyeth Nutritionals for the development and commercialization ... formulas. The announcement follows shortly after Neose's deal with Johnson & Johnson subsidiary ...

Article: WYETH STOPS HEART ATTACK STUDY; NEOSE LOSES ...
BIOWORLD Today;  May 13, 2002 ;     700+ words ... ... five months after Neose Technologies Inc. signed a deal with Wyeth to provide Phase ... N.J.-based Wyeth, formerly named ... entailed the license of Neose's GlycoAdvance ... ingredients. Kremer said Neose is optimistic about ... can see through the Wyeth misfortune. "Glycosylation ...

Article: Neose Technologies. (Active Pharmaceutical Ingredient ...
Chemical Market Reporter;  May 20, 2002 ;     537 words ...NEOSE Technologies reports Wyeth Pharmaceuticals does not intend to continue clinical development of rPSGL-Ig (P-selectin glycoprotein ligand) for myocardial infarction due to disappointing results in Phase II trials.

Article: Analysis of Neose Technologies Inc.
M2 Presswire;  March 20, 2007 ;     700+ words ... ... important disease-fighting properties. Neose is developing a malignant melanoma ... with Neuronyx. It is also helping Wyeth's pharmaceutical division develop ... to produce a recombinant protein. Neose and Wyeth's nutritionals division are working ...